11 January 2021

Moderna has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Covid-19 Vaccine Moderna, its mRNA vaccine candidate to fight the SARS-CoV-2 virus, under Regulation 174. The authorisation allows the Covid-19 Vaccine Moderna to be supplied to the UK on an emergency and temporary basis.

Humanigen and Eversana have announced a partnership to launch and commercialise Lenzilumab for treating hospitalised and hypoxic Covid-19 patients. However, this would only occur after the US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the recombinant monoclonal antibody.

Biotech COVAXX has announced it has commenced pre-clinical work, design and testing of a second vaccine candidate to address the recent SARS-CoV-2 viral mutations, and particularly the South African variant.

The FDA of the Philippines has approved Clover Biopharmaceuticals’ clinical trial application for its Covid-19 vaccine in the country. The regulator also stated it has approved a clinical trial for the vaccine developed by Clover Australia. The approval makes Clover the second biopharmaceutical company to have received the go-ahead to conduct Covid-19 vaccine trials in the Philippines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.